Sintilimab, IBI305, and Chemotherapy Show Promise in First-Line Advanced Gastric and GEJ Adenocarcinoma
Advanced gastric and gastroesophageal junction cancers are receiving renewed attention after researchers reported a clinical study testing a three-part first-line ...
